|Application ||WB, E|
|Description||Basic helix-loop-helix (bHLH) transcription factors have been implicated in cell lineage determination and differentiation. The protein encoded by this gene is a bHLH transcription factor and shares similarity with another bHLH transcription factor, Dermo1. The strongest expression of this mRNA is in placental tissue; in adults, mesodermally derived tissues express this mRNA preferentially. Mutations in this gene have been found in patients with Saethre-Chotzen syndrome.|
|Immunogen||Purified recombinant fragment of human TWIST1 (AA: 9-74) expressed in E. Coli.|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Other Names||Twist-related protein 1, Class A basic helix-loop-helix protein 38, bHLHa38, H-twist, TWIST1, BHLHA38, TWIST|
WB~~1/500 - 1/2000
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||TWIST1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Acts as a transcriptional regulator. Inhibits myogenesis by sequestrating E proteins, inhibiting trans-activation by MEF2, and inhibiting DNA-binding by MYOD1 through physical interaction. This interaction probably involves the basic domains of both proteins. Also represses expression of proinflammatory cytokines such as TNFA and IL1B. Regulates cranial suture patterning and fusion. Activates transcription as a heterodimer with E proteins. Regulates gene expression differentially, depending on dimer composition. Homodimers induce expression of FGFR2 and POSTN while heterodimers repress FGFR2 and POSTN expression and induce THBS1 expression. Heterodimerization is also required for osteoblast differentiation. Represses the activity of the circadian transcriptional activator: NPAS2-ARNTL/BMAL1 heterodimer (By similarity).|
|Tissue Location||Subset of mesodermal cells.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1.J Cancer Res Clin Oncol. 2011 Oct;137(10):1487-93. 2.Cancer Res. 2011 Jan 1;71(1):245-54.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.